ATE466093T1 - Rekombinanter adeno-assoziierter virusvektor zur behandlung von morbus alzheimer - Google Patents

Rekombinanter adeno-assoziierter virusvektor zur behandlung von morbus alzheimer

Info

Publication number
ATE466093T1
ATE466093T1 AT04745818T AT04745818T ATE466093T1 AT E466093 T1 ATE466093 T1 AT E466093T1 AT 04745818 T AT04745818 T AT 04745818T AT 04745818 T AT04745818 T AT 04745818T AT E466093 T1 ATE466093 T1 AT E466093T1
Authority
AT
Austria
Prior art keywords
associated virus
virus vector
alzheimer
disease
treatment
Prior art date
Application number
AT04745818T
Other languages
English (en)
Inventor
Takeshi Tabira
Hideo National Hara
Original Assignee
Japan Government
Nat Inst Of Biomedical Innovat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Government, Nat Inst Of Biomedical Innovat filed Critical Japan Government
Application granted granted Critical
Publication of ATE466093T1 publication Critical patent/ATE466093T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/861—Adenoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Plant Pathology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04745818T 2003-06-13 2004-06-11 Rekombinanter adeno-assoziierter virusvektor zur behandlung von morbus alzheimer ATE466093T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2003169714 2003-06-13
JP2003371103A JP4888876B2 (ja) 2003-06-13 2003-10-30 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター
PCT/JP2004/008224 WO2004111250A1 (ja) 2003-06-13 2004-06-11 アルツハイマー病の治療のための組換えアデノ随伴ウィルスベクター

Publications (1)

Publication Number Publication Date
ATE466093T1 true ATE466093T1 (de) 2010-05-15

Family

ID=33554414

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04745818T ATE466093T1 (de) 2003-06-13 2004-06-11 Rekombinanter adeno-assoziierter virusvektor zur behandlung von morbus alzheimer

Country Status (15)

Country Link
US (1) US8318687B2 (de)
EP (1) EP1634956B1 (de)
JP (1) JP4888876B2 (de)
KR (1) KR20060029225A (de)
AT (1) ATE466093T1 (de)
AU (1) AU2004248014B2 (de)
BR (1) BRPI0411321A (de)
CA (1) CA2529179C (de)
DE (1) DE602004026867D1 (de)
DK (1) DK1634956T3 (de)
ES (1) ES2345151T3 (de)
NZ (1) NZ544554A (de)
PT (1) PT1634956E (de)
RU (1) RU2335542C2 (de)
WO (1) WO2004111250A1 (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
KR100677051B1 (ko) 2005-03-18 2007-02-01 주식회사 엘지화학 올레핀으로부터 불포화산을 제조하는 방법
WO2006112553A2 (en) * 2005-04-20 2006-10-26 Dnavec Corporation Highly safe intranasally administrable gene vaccines for treating alzheimer's disease
CN101228272A (zh) * 2005-04-20 2008-07-23 生物载体株式会社 用于治疗阿尔茨海默病的具有较高安全性的经鼻腔内给药基因疫苗
WO2006126682A1 (ja) * 2005-05-27 2006-11-30 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute アルツハイマー病の予防・治療用ワクチン
US8785353B2 (en) 2005-06-23 2014-07-22 Keygene N.V. Strategies for high throughput identification and detection of polymorphisms
CA2910861C (en) 2005-09-29 2018-08-07 Michael Josephus Theresia Van Eijk High throughput screening of mutagenized populations
US10316364B2 (en) 2005-09-29 2019-06-11 Keygene N.V. Method for identifying the source of an amplicon
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
ES2882401T3 (es) 2005-12-22 2021-12-01 Keygene Nv Método de detección de polimorfismos basado en AFLP de alto rendimiento
EP2002017B1 (de) 2006-04-04 2015-06-10 Keygene N.V. Nachweis von molekularmarkern mit hohem durchsatz auf der basis von restriktionsfragmenten
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8673846B2 (en) 2009-11-02 2014-03-18 Toagosei Co. Ltd. Cell proliferation-promoting peptide and use thereof
CN102711812B (zh) 2010-01-08 2014-07-16 国立大学法人京都大学 Tau蛋白病治疗用疫苗
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9238796B2 (en) 2010-06-04 2016-01-19 Toagosei Co. Ltd. Cell growth-promoting peptide and use thereof
US8822408B2 (en) 2010-06-04 2014-09-02 Toagosei Co., Ltd. Cell growth-promoting peptide and use thereof
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
JP6342886B2 (ja) 2012-04-18 2018-06-13 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ Ａａｖカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法
US9370182B2 (en) 2012-05-28 2016-06-21 Toagosei Co., Ltd. Antimicrobial peptide and use thereof
JP6311935B2 (ja) 2012-10-18 2018-04-18 東亞合成株式会社 ２型ｔｎｆ受容体の発現を抑制する合成ペプチド及びその利用
EP3027205A4 (de) 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Impfstoffformulierungen zur induzierung einer th2-immunantwort
US10577627B2 (en) 2014-06-09 2020-03-03 Voyager Therapeutics, Inc. Chimeric capsids
EP3215191B1 (de) 2014-11-05 2024-08-14 Voyager Therapeutics, Inc. Aadc-polynukleotide zur behandlung von morbus parkinson
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
KR20230145206A (ko) 2014-11-14 2023-10-17 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
AU2016362477A1 (en) 2015-12-02 2018-06-14 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
EP3448987A4 (de) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
EP3448874A4 (de) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
US10584337B2 (en) 2016-05-18 2020-03-10 Voyager Therapeutics, Inc. Modulatory polynucleotides
IL297576B2 (en) 2016-05-18 2024-02-01 Voyager Therapeutics Inc Compositions and methods of treating huntington's disease
EP3831281B1 (de) 2016-08-30 2026-02-25 The Regents of The University of California Vorrichtungen und systeme für biomedizinische zielführung und verabreichung
WO2018127702A1 (en) 2017-01-06 2018-07-12 Stabilitech Biopharma Ltd Virus
EP3618839A4 (de) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. Zusammensetzungen und verfahren zur behandlung von amyotropher lateralsklerose (als)
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
US11512327B2 (en) 2017-08-03 2022-11-29 Voyager Therapeutics, Inc. Compositions and methods for delivery of AAV
MX2020003042A (es) 2017-09-29 2020-11-18 Voyager Therapeutics Inc Rescate del fenotipo neurológico central y periférico de la ataxia de friedreich mediante administración intravenosa.
TW202413649A (zh) 2017-10-16 2024-04-01 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
CN112424359A (zh) 2018-05-15 2021-02-26 沃雅戈治疗公司 用于治疗帕金森氏病的组合物和方法
WO2020030954A1 (en) 2018-08-09 2020-02-13 Integrative Medicine Clinic, Sia Theranostics-like protein sanps conjugated to integrin and pmsa targeting peptides and therapy of prostate cancer
US12281321B2 (en) 2018-09-28 2025-04-22 Voyager Therapeutics, Inc. Frataxin expression constructs having engineered promoters and methods of use thereof
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
BR112023001456A2 (pt) 2020-07-27 2023-04-11 Voyager Therapeutics Inc Composições e métodos para o tratamento de distúrbios neurológicos relacionados à deficiência de beta glicosilceramidase
US20230285596A1 (en) 2020-07-27 2023-09-14 Voyager Therapeutics, Inc Compositions and methods for the treatment of niemann-pick type c1 disease
EP4262846A4 (de) * 2020-12-18 2024-11-20 Baylor College of Medicine Verabreichung von abeta-varianten zur aggregationshemmung
US20250049955A1 (en) 2021-11-17 2025-02-13 Voyager Therapeutics, Inc. Compositons and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency
AU2023427408A1 (en) 2023-02-02 2025-09-04 Voyager Therapeutics, Inc. Compositions and methods for the treatment of neurological disorders related to glucosylceramidase beta deficiency

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2214247C (en) * 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
US5858351A (en) 1996-01-18 1999-01-12 Avigen, Inc. Methods for delivering DNA to muscle cells using recombinant adeno-associated virus vectors
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
AU2486900A (en) * 1998-12-29 2000-07-31 University Of Georgia Research Foundation, Inc., The Rubredoxin fusion proteins, protein expression system and methods
WO2001006989A2 (en) * 1999-07-27 2001-02-01 Abgenix, Inc. Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders
US20030165481A1 (en) * 2000-02-24 2003-09-04 Hersh Louis B. Amyloid peptide inactivating enzyme to treat Alzheimer's disease
US20040072753A1 (en) * 2000-11-01 2004-04-15 Milton Nathaniel Gavin Nicolas Peptides for use in the treatment of alzheimer's disease
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
CN100450551C (zh) * 2002-11-29 2009-01-14 中国医学科学院基础医学研究所 用于治疗和预防阿尔茨海默病的重组腺相关病毒基因疫苗及其用途

Also Published As

Publication number Publication date
EP1634956B1 (de) 2010-04-28
JP4888876B2 (ja) 2012-02-29
ES2345151T3 (es) 2010-09-16
PT1634956E (pt) 2010-06-23
RU2006101149A (ru) 2006-06-27
RU2335542C2 (ru) 2008-10-10
WO2004111250A1 (ja) 2004-12-23
CA2529179C (en) 2012-08-21
US20090004144A1 (en) 2009-01-01
AU2004248014A1 (en) 2004-12-23
NZ544554A (en) 2010-06-25
JP2005021149A (ja) 2005-01-27
KR20060029225A (ko) 2006-04-05
AU2004248014B2 (en) 2008-12-04
BRPI0411321A (pt) 2006-07-18
US8318687B2 (en) 2012-11-27
CA2529179A1 (en) 2004-12-23
EP1634956A1 (de) 2006-03-15
DK1634956T3 (da) 2010-08-16
DE602004026867D1 (de) 2010-06-10
EP1634956A4 (de) 2007-01-24

Similar Documents

Publication Publication Date Title
DE602004026867D1 (de) Rekombinanter adeno-assoziierter virusvektor zur behandlung von morbus alzheimer
AU9063801A (en) Methods and compositions for diseases associated with amyloidosis
DE60221665D1 (de) Impfstoff zur verhütung und behanldung von alzheimer-demenz und von amyloid-bezogenen krankheiten
ATE277081T1 (de) Inhibitoren des humanplasmins, die sich von den kunitz domänen ableiten
DE602004022061D1 (de) Verwendung von modifizierten cyclosporinen zur behandlung von hcv-erkrankungen
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
DE60232577D1 (de) Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential
DE602004021797D1 (de) Behandlung von alzheimer-krankheit und amyloider gehirnangiopathie
ATE454403T1 (de) Menschliche koagulationsfaktor vii polypeptide
ATE386104T1 (de) Substanzen zur vorbeugung und behandlung von autoimmunkrankheiten
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
DK2380583T3 (da) Små peptider til behandling af Alzheimers sygdom og andre beta-amyloidprotein-fibrillogeneseforstyrrelser
DE60035523D1 (de) Optimierte minigene und dadurch kodierte peptide
DE602004029465D1 (de) Externes Präparat zur Behandlung von Fusspilz
EP1499349A4 (de) Rekombinante hybrid-allergenkonstrukte mit verringerter allergenität unter beibehaltung der immunogenität des natürlichen allergens
WO2004096856A3 (en) Secreted protein family
DE60128399D1 (de) Verwendung von thrombomodulinanaloga zur regenerierung von rückenmarkverletzungen
EP1734827A4 (de) Verfahren und zusammensetzungen zur behandlung von mit anomaler mikrosatellitenexpansion in verbindung stehenden krankheiten
DE60124093D1 (de) S-methyl-dihydro-ziprasidon zur Behandlung von Augenerkrankungen.
ATE329032T1 (de) Haemophilus influenza äusseres membranprotein und verwendung davon als impstoff
ATE394420T1 (de) Gen in zusammenhang mit haarausfall, das davon kodierte polypeptid und anwendungen dafür
ATE397753T1 (de) Screening-verfahren für eine prophylaktische und therapeutische substanz für eine nierenerkrankung
DE60223674D1 (de) Vektoren zur gesteigerten expression von vegf zur behandlung von krankheiten
DE112004001630D2 (de) Peptidtoxine zur Behandlung von Übergewicht
BR0108557A (pt) Peptìdeos de tlp e sequências de dna codificando os mesmos

Legal Events

Date Code Title Description
EEIH Change in the person of patent owner
REN Ceased due to non-payment of the annual fee